Guidelines for the appropriate use of non‐steroidal anti‐inflammatory drugs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitors in patients requiring chronic anti‐inflammatory therapy
Open Access
- 14 January 2004
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 19 (2), 197-208
- https://doi.org/10.1111/j.0269-2813.2004.01834.x
Abstract
Aim : To rationalize decision making around the use of different non‐steroidal anti‐inflammatory drug (NSAID) treatment strategies in patients with varying degrees of gastrointestinal and cardiovascular risk. Methods : The panel comprised nine physicians (three rheumatologists, two internists, two gastroenterologists and two cardiologists) from geographically diverse areas practising in community‐based settings (n = 4) and academic institutions (n = 5). A literature review was performed by the authors on the risks, benefits and costs of NSAIDs, cyclo‐oxygenase‐2‐specific inhibitors and proton pump inhibitor co‐therapy. The RAND/UCLA Appropriateness Method was used to rate 304 clinical scenarios as ‘appropriate’, ‘uncertain’ or ‘inappropriate’. Results : In patients with no previous gastrointestinal event and not concurrently on aspirin (low risk), the panel rated the use of an NSAID alone as ‘appropriate’ for those aged < 65 years, and the use of an NSAID +proton pump inhibitor or cyclo‐oxygenase‐2‐specific inhibitor + proton pump inhibitor as ‘inappropriate’. For patients aged > 65 years and at low risk, an NSAID or cyclo‐oxygenase‐2‐specific inhibitor alone was rated as ‘uncertain’. For patients with a previous gastrointestinal event or who concurrently received aspirin, an NSAID alone was rated as ‘inappropriate’, and either a cyclo‐oxygenase‐2‐specific inhibitor or an NSAID +proton pump inhibitor was rated as ‘appropriate’. Finally, for patients with a previous gastrointestinal event and on aspirin, an NSAID or cyclo‐oxygenase‐2‐specific inhibitor in conjunction with a proton pump inhibitor was rated as ‘appropriate’. Conclusions : Clinicians and managed care entities need to balance the risks, benefits and costs of NSAIDs, cyclo‐oxygenase‐2‐specific inhibitors and the prophylactic use of proton pump inhibitors. The guidelines given here can assist this process.Keywords
This publication has 46 references indexed in Scilit:
- Serious lower gastrointestinal clinical events with nonselective NSAID or coxib useGastroenterology, 2003
- Lansoprazole for the Prevention of Recurrences of Ulcer Complications from Long-Term Low-Dose Aspirin UseNew England Journal of Medicine, 2002
- Upper gastrointestinal bleeding among users of NSAIDs: a population‐based cohort study in DenmarkBritish Journal of Clinical Pharmacology, 2002
- Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studiesBritish Journal of Clinical Pharmacology, 2001
- Preventing Recurrent Upper Gastrointestinal Bleeding in Patients withHelicobacter pyloriInfection Who Are Taking Low-Dose Aspirin or NaproxenNew England Journal of Medicine, 2001
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Validity of criteria used for detecting underuse of coronary revascularizationPublished by American Medical Association (AMA) ,1995
- Nonsteroidal antiinflammatory drugs and dyspepsia in the elderlyDigestive Diseases and Sciences, 1995
- Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer diseaseArchives of Internal Medicine, 1993
- Extension of Multiple Range Tests to Group Means with Unequal Numbers of ReplicationsBiometrics, 1956